Ftse Mib
38.779,67
0,68%
DAX
23.419,48
1,30%
S&P 500
5.738,52
-1,78%
NASDAQ
18.069,26
-2,61%
Bitcoin
87.837,59
-2,33%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NYSE AbbVie Inc (ABBV) AbbVie Inc (ABBV) Notizie

ABBV

AbbVie (ABBV)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:ABBV
DataOraFonteTitoloSimboloCompagnia
04/03/202523:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
04/03/202514:00PR Newswire (Canada)SKYRIZI® (risankizumab) Now Available for Moderately to Severely Active Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel DiseaseNYSE:ABBVAbbVie Inc
04/03/202514:00PR Newswire (US)AbbVie to Present at the Leerink Partners Global Healthcare ConferenceNYSE:ABBVAbbVie Inc
04/03/202514:00PR Newswire (Canada)SKYRIZI® (risankizumab) est maintenant offert pour le traitement de la colite ulcéreuse modérément à fortement évolutive, élargissant la gamme de traitements offerts par AbbVie contre les maladies inflammatoires de l'intestinNYSE:ABBVAbbVie Inc
03/03/202522:28Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:ABBVAbbVie Inc
03/03/202507:11PR Newswire (US)AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of ObesityNYSE:ABBVAbbVie Inc
28/02/202508:00PR Newswire (US)AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell ArteritisNYSE:ABBVAbbVie Inc
26/02/202523:04Edgar (US Regulatory)Form 8-K - Current reportNYSE:ABBVAbbVie Inc
26/02/202514:00PR Newswire (US)AbbVie to Present at the TD Cowen's 45th Annual Health Care ConferenceNYSE:ABBVAbbVie Inc
20/02/202523:00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:ABBVAbbVie Inc
18/02/202522:15Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNYSE:ABBVAbbVie Inc
14/02/202522:31Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNYSE:ABBVAbbVie Inc
14/02/202513:40PR Newswire (US)AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of DirectorsNYSE:ABBVAbbVie Inc
13/02/202517:57PR Newswire (US)AbbVie Declares Quarterly DividendNYSE:ABBVAbbVie Inc
12/02/202514:30PR Newswire (US)Allergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S. Expanding Access to High Quality Aesthetics TrainingNYSE:ABBVAbbVie Inc
12/02/202513:33GlobeNewswire Inc.AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated ImmunotherapiesNYSE:ABBVAbbVie Inc
07/02/202522:00Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NYSE:ABBVAbbVie Inc
07/02/202519:27PR Newswire (US)U.S. FDA Approves EMBLAVEO™ (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment OptionsNYSE:ABBVAbbVie Inc
06/02/202514:05PR Newswire (US)Allergan Aesthetics Invites Consumers to Join the Faces of Natrelle® CampaignNYSE:ABBVAbbVie Inc
05/02/202515:00PR Newswire (US)Allergan Aesthetics, the American Society of Plastic Surgeons (ASPS) and The Aesthetic Society Release Two New Engaging LIMITLESS Videos Celebrating Women SurgeonsNYSE:ABBVAbbVie Inc
31/01/202513:36PR Newswire (US)AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial ResultsNYSE:ABBVAbbVie Inc
29/01/202510:00PR Newswire (US)Allergan Aesthetics launches new AA Signature Program at IMCAS 2025 to redefine patient-centric, multimodal treatment plansNYSE:ABBVAbbVie Inc
24/01/202510:00PR Newswire (US)Allergan Aesthetics unveils new AA Signature Program and immersive booth at IMCAS World Congress 2025NYSE:ABBVAbbVie Inc
23/01/202515:16PR Newswire (US)AbbVie Completes Acquisition of Nimble TherapeuticsNYSE:ABBVAbbVie Inc
23/01/202515:00PR Newswire (US)AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and ImmunologyNYSE:ABBVAbbVie Inc
13/01/202515:00PR Newswire (US)AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple MyelomaNYSE:ABBVAbbVie Inc
13/01/202514:31PR Newswire (US)AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical ProgramNYSE:ABBVAbbVie Inc
09/01/202514:00PR Newswire (US)AbbVie to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNYSE:ABBVAbbVie Inc
07/01/202514:00PR Newswire (US)CoolMonth is Back With Deals on CoolSculpting® Elite by Allergan AestheticsNYSE:ABBVAbbVie Inc
03/01/202514:00PR Newswire (US)AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference CallNYSE:ABBVAbbVie Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:ABBV

La tua Cronologia

USOTC
MDRKF
Mandarake (PK)
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci